Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy DOI Creative Commons
Rositsa Mihaylova, Denitsa Momekova,

Viktoria Elincheva

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1701 - 1701

Published: Dec. 17, 2024

The present review provides a detailed and comprehensive discussion on antibody–drug conjugates (ADCs) as an evolving new modality in the current therapeutic landscape of malignant diseases. principle concepts targeted delivery highly toxic agents forsaken stand-alone drugs are examined detail, along with biochemical technological tools for their successful implementation. An extensive analysis ADCs’ major components is conducted parallel function impact stability, efficacy, safety, resistance profiles immunoconjugates. scope article covers classes currently validated natural compounds used payloads, emphasis structural mechanistic features, origin, distribution. Future perspectives design thoroughly explored, addressing inherent or emerging challenges limitations. survey also overview molecular rationale active tumor targeting ADC-based platforms, exploring cellular biology clinical relevance markers “homing” mechanism both hematological solid malignancies.

Language: Английский

Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2 DOI Creative Commons
Matej Maršić, Nives Jonjić, Maja Gligora Marković

et al.

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(5), P. 296 - 296

Published: April 23, 2025

Nectin-2 and Nectin-4 are cell adhesion molecules associated with the progression of various cancers. The main goal this pilot study was to evaluate expression patterns in laryngeal squamous carcinoma (LSCC). A retrospective conducted on tissue microarray (TMA) samples derived from 31 patients who underwent total laryngectomy. findings revealed heterogenous both tumor cells surrounding stroma, being significantly higher than expression. Specifically, 74% cases showed weak cytoplasmic staining for Nectin-2, while 41.93% exhibited strong Nectin-4. Both expressions were more pronounced at invasive margins. Although no significant differences observed across grades (W = 83.500; z −0.463; p 0.658), noted. Well-differentiated tumors (Grade 1), 80.65% cases, predominantly membranous staining, including epithelial mucosal surface. Conversely, less-differentiated 2 3), a shift toward evident. 74.19% Grade 100% 3 predominant localization This transition also evident normal superficial epithelium malignant tissue. These observations suggest that alterations subcellular may be carcinogenesis could serve as potential markers assessment precancerous lesions aggressiveness tumors.

Language: Английский

Citations

0
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: a systematic review and meta-analysis DOI
Silvia Belloni, Paola Tiberio, Rita De Sanctis

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 204, P. 104527 - 104527

Published: Oct. 10, 2024

Language: Английский

Citations

1
Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment DOI
Lili Xu, Pengtao Xu, Jingsong Wang

et al.

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: unknown, P. 177202 - 177202

Published: Dec. 1, 2024

Language: Английский

Citations

1
Future investigative directions for novel therapeutic targets in head and neck cancer DOI
Jacqueline P. Nguyen,

Liam C Woerner,

Daniel E. Johnson

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: 24(11), P. 1067 - 1084

Published: Oct. 16, 2024

Here we describe novel agents, their mechanism(s) of action, preclinical results, and ongoing clinical trials in HNSCC.

Language: Английский

Citations

0
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study DOI Creative Commons

Dora Niedersuess-Beke,

Karl Mayrhofer,

Johanna Krauter

et al.

Clinical Genitourinary Cancer, Journal Year: 2024, Volume and Issue: unknown, P. 102278 - 102278

Published: Nov. 1, 2024

Language: Английский

Citations

0
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy DOI Open Access

Xue Jiang,

Wan Najbah Nik Nabil,

Yufei Ze

et al.

Phytotherapy Research, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

ABSTRACT Natural compound‐derived chemotherapies remain central to cancer treatment, however, they often cause off‐target side effects that negatively impact patients' quality of life. In contrast, antibody‐drug conjugates (ADCs) combine cytotoxic payloads with antibodies specifically target cells. Most approved and clinically investigated ADCs utilize naturally derived payloads, while those conventional synthetic molecular limited. This review focuses on enhance the efficacy by linking them antibodies. We provide an overview core components ADCs, their working mechanisms, FDA‐approved featuring such as calicheamicin, camptothecin, dolastatin 10, maytansine, pyrrolbenzodiazepine (PBD), immunotoxin Pseudomonas exotoxin A. also explores recent clinical advancements aimed at broadening therapeutic potential applicability in treating heterogeneously composed tumors use beyond oncology. Additionally, this highlights are currently being but have not yet received approval. By summarizing current landscape, provides insights into promising avenues for exploration contributes refinement treatment protocols improved patient outcomes.

Language: Английский

Citations

0
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy DOI Creative Commons
Rositsa Mihaylova, Denitsa Momekova,

Viktoria Elincheva

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1701 - 1701

Published: Dec. 17, 2024

The present review provides a detailed and comprehensive discussion on antibody–drug conjugates (ADCs) as an evolving new modality in the current therapeutic landscape of malignant diseases. principle concepts targeted delivery highly toxic agents forsaken stand-alone drugs are examined detail, along with biochemical technological tools for their successful implementation. An extensive analysis ADCs’ major components is conducted parallel function impact stability, efficacy, safety, resistance profiles immunoconjugates. scope article covers classes currently validated natural compounds used payloads, emphasis structural mechanistic features, origin, distribution. Future perspectives design thoroughly explored, addressing inherent or emerging challenges limitations. survey also overview molecular rationale active tumor targeting ADC-based platforms, exploring cellular biology clinical relevance markers “homing” mechanism both hematological solid malignancies.

Language: Английский

Citations

0